Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.

Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC.

Cancer Res. 1997 Nov 1;57(21):4667-72.

2.

Urothelial overexpression of insulin-like growth factor-1 increases susceptibility to p-cresidine-induced bladder carcinogenesis in transgenic mice.

Hursting SD, Perkins SN, Lavigne JA, Beltran L, Haines DC, Hill HL, Alvord WG, Barrett JC, DiGiovanni J.

Mol Carcinog. 2009 Aug;48(8):671-7. doi: 10.1002/mc.20548.

PMID:
19415693
4.
5.

Effect of Dietary Restriction on Toxicology and Carcinogenesis Studies in F344/N Rats and B6C3F1 Mice.

National Toxicology Program .

Natl Toxicol Program Tech Rep Ser. 1997 Sep;460:1-414.

6.

Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction.

Kari FW, Dunn SE, French JE, Barrett JC.

J Nutr Health Aging. 1999;3(2):92-101. Review.

PMID:
10885804
7.

Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice.

Shimizu M, Shirakami Y, Iwasa J, Shiraki M, Yasuda Y, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.

Clin Cancer Res. 2009 May 1;15(9):3068-75. doi: 10.1158/1078-0432.CCR-08-2093. Epub 2009 Apr 14.

8.

Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation.

Lee CC, Yamamoto S, Wanibuchi H, Wada S, Sugimura K, Kishimoto T, Fukushima S.

Cancer Res. 1997 Nov 1;57(21):4765-76.

9.

Genetic and molecular markers of urothelial premalignancy and malignancy.

Cordon-Cardo C, Cote RJ, Sauter G.

Scand J Urol Nephrol Suppl. 2000;(205):82-93. Review.

PMID:
11144907
10.

Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression.

Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK.

J Natl Cancer Inst. 1999 Mar 17;91(6):512-23.

PMID:
10088621
11.

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K.

Cancer Res. 2000 Oct 15;60(20):5599-602.

12.

[Expression of IGF-I and IGF-IR in bladder cancer].

Xie QX, Lin XC, Zhang MF, Han CX, Guo YH.

Ai Zheng. 2004 Jun;23(6):707-9. Chinese.

PMID:
15191677
13.

Diet and cancer prevention studies in p53-deficient mice.

Hursting SD, Perkins SN, Phang JM, Barrett JC.

J Nutr. 2001 Nov;131(11 Suppl):3092S-4S. Review.

14.

Energy balance, physical activity, and cancer risk.

Fair AM, Montgomery K.

Methods Mol Biol. 2009;472:57-88. doi: 10.1007/978-1-60327-492-0_3. Review.

PMID:
19107429
15.

Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.

Shariat SF, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM.

Urology. 2003 Feb;61(2):359-64.

PMID:
12597948
16.
17.

Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.

Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D.

Cancer Res. 2002 Feb 15;62(4):1030-5.

18.

Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53.

Lee CC, Ichihara T, Yamamoto S, Wanibuchi H, Sugimura K, Wada S, Kishimoto T, Fukushima S.

Carcinogenesis. 1999 Sep;20(9):1697-708.

PMID:
10469613
19.
20.

Supplemental Content

Support Center